MJFF's Targets-to-Therapies (T2T) 2025 Program Summary

MJFF’s Targets-to-Therapies (T2T) program is accelerating Parkinson’s drug discovery by closing validation gaps for priority targets. In 2025, expert-led teams advanced NOD2, TMEM175, MCOLN1, ATP13A2, and OGA, building models, biomarkers, and assays to clarify disease biology. T2T also invested in shared research tools: knockout-validated antibodies, new iPSC lines, and mouse models that will be openly distributed to the community. Alongside target work, MJFF developed a framework to prioritize targets and other non-pharmacological approaches for key symptoms and launched the online T2T Target Explorer to share progress and results. Updates will continue through 2026, including expanded validation calls and target funding.